CTLA4 and pachyonychia congenita: For example, a phase 1 trial (NCT04301414) is investigating the use of neoadjuvant degarelix acetate +/− non-fucosylated anti-CTLA-4 (BMS-986218) in men with high-risk localized PC (cT1c-T3bN0, Gleason sum of ≥4 + 3) [151].